Loading...
History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology
BACKGROUND: Exogenous replacement of erythropoietin by recombinant human erythropoietin has been considered a standard of care for the treatment of anemia in patients with chronic kidney disease for more than 20 years. Genetically-engineered biologic proteins derived from human, animal, or microorga...
Na minha lista:
| Udgivet i: | Am J Nephrol |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5405152/ https://ncbi.nlm.nih.gov/pubmed/28142147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000455387 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|